is a spin-out company from the IVTLab at the University of Helsinki, Finland. Valo Tx has assembled a uniquely talented team of oncolytic virus and immunotherapy experts, who together with the founding scientist have the necessary expertise to take its patented technology through clinical development and make it available to patients. The management team has a proven track record of developing successful companies from a laboratory idea to a full stock exchange listing.
Valo Tx is positioned to transform the field of immunotherapy in cancer and infectious disease. Valo Tx’s technology uniquely combines the best qualities of several distinct clinically proven immunotherapy concepts – oncolytic virus therapy, peptide vaccination and viral vector-based immunotherapy. Our technology platform is able to deliver many different antigens through coating the surface of a wide range of vectors, including but not limited to adenoviruses, enveloped viruses and bacteria
Valo Tx’s proprietary technology allows the binding of disease-targeting peptides to the surface of oncolytic or infectious disease vectors, thereby eliciting an enhanced T-cell driven immune response to destroy the targeted tumor or pathogen. The disease associated peptides are easily and rapidly combined with the vector by leveraging electrostatic interactions and membrane penetrating peptides rather than through generating disease antigens by genetically engineering the vector. This method enables the rapid creation of multiple vector-based immunotherapies that promise to provide lasting immunity to many different cancer types and pathogens. This approach also addresses the need for rapidly adaptable disease-specific and even personalised therapies. In infectious disease, Valo Tx’s vectors can, for example, deliver coronavirus associated proteins common across the coronavirus family to create a pan-Coronavirus vaccine as a potential solution to the current and future global pandemics.